Other Mutations: MTAP

NCT05275478: Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

NCT05275478
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MTAP
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have tumors that express a homozygous deletion of the MTAP gene
Exclusions: Patients with central nervous system metastases associated with progressive neurological symptoms
https://ClinicalTrials.gov/show/NCT05275478

NCT05245500: Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion

NCT05245500
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MTAP
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have tumors that express a homozygous deletion of the MTAP gene
Exclusions: Patients with prior treatment of a PRMT5 or MAT2A inhibitor therapy; Patients with active brain metastases; Patients with leptomeningeal disease
https://ClinicalTrials.gov/show/NCT05245500

Up ↑